相关实验视频

Updated: Sep 9, 2025

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

甲状腺转录因子-1 阴性非状细胞非小细胞肺癌的治疗反应和存活率

Yutaka Takahara¹, Ryudai Abe¹, Sumito Nagae¹

¹Department of Respiratory Medicine, Kanazawa Medical University, Ishikawa, Japan.

Cancer diagnosis & prognosis

|September 3, 2025

概括

对于甲状腺转录因子-1 (TTF-1) 阴性非小细胞肺癌 (NSCLC),以白金为基础的化疗改善了治疗反应和存活率. 这种策略推给TTF-1阴性NSCLC患者使用.

科学领域:

癌症学
医学研究

背景情况:

甲状腺转录因子-1 (TTF-1) 阴性非状非小细胞肺癌 (NS-NSCLC) 对佩米雷克斯德和免疫疗法等标准疗法反应有限.
对TTF-1阴性NSCLC的最佳第一线治疗策略仍未确定.
贝瓦西祖马布已经显示出改善结果的潜力,但证据有限.

研究的目的:

确定对TTF-1阴性NSCLC的第一线治疗反应的临床特征.
确定该患者群体治疗反应的预测因素.
为TTF-1阴性NS-NSCLC提出最佳治疗策略.

主要方法:

对TTF- 1阴性NSCLC患者的回顾性分析.
根据第一线治疗的疗效将患者分为响应群和不响应群.
对治疗反应的预测因素的分析.

主要成果:

在29名患者中,有7名患者 (24. 1%) 反应良好.
在响应者中,以为基础的联合治疗更为频繁 (p=0. 023).
在响应者中观察到较低的中性细胞/ 淋巴细胞比率 (p=0. 001).
添加贝瓦西祖马布可以独立预测治疗反应 (OR=33. 406, p=0. 035).
受试者整体存活时间显著增加 (p=0. 008).

结论:

基于的组合疗法,特别是贝瓦齐祖马布,提高了TTF- 1阴性NSCLC的响应率.
贝瓦西祖马布是治疗反应和改善存活率的重要预测因素.
这种组合疗法是治疗TTF- 1阴性NSCLC的一个有希望的策略.

关键词:

在TTF-1 一个TTF-1负的NS-NSCLC 贝瓦西祖马布一线治疗预测因素

更多相关视频

Establishment and Characterization of Patient-Derived Xenograft Models of Anaplastic Thyroid Carcinoma and Head and Neck Squamous Cell Carcinoma

Establishment and Characterization of Patient-Derived Xenograft Models of Anaplastic Thyroid Carcinoma and Head and Neck Squamous Cell Carcinoma

Published on: June 2, 2023

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

Published on: November 22, 2021

相关概念视频

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...